Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2023-08-01 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company for its subsidiaries. It includes specifics about guarantee contracts, amounts, counterparties, and board approvals. The content focuses on financing guarantees rather than financial results or management changes. The document length is 3782 characters, which is relatively short but contains substantive information about guarantees rather than just announcing a report publication. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about financing guarantees, which fits best under Capital/Financing Update (CAP).
2023-08-01 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details the guarantee contract signed with a bank, the amount guaranteed, the financial status of the subsidiary, and the board's opinion on the guarantee. The document is relatively short (2044 characters) and focuses on a specific financing guarantee event rather than comprehensive financial results or reports. It does not contain full financial statements or detailed financial analysis. It is an update on financing-related activities, specifically guarantees provided by the company to its subsidiaries. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-06-30 Chinese
关于签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the signing of a strategic cooperation framework agreement with another company. It details the nature of the agreement, the parties involved, the scope of cooperation, and the impact on the company's business. It explicitly states that the agreement is a framework and does not constitute a substantive transaction or major asset restructuring. The document also includes disclosures about recent share transactions by senior management and confirms no major shareholding changes or plans to reduce holdings. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (3372 characters) and serves as a regulatory announcement about a strategic cooperation agreement and related disclosures. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive information rather than just announcing a report's release. It is not a call transcript, capital update, or legal proceeding report. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-06-12 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company to its subsidiaries. It includes specifics about guarantee contracts, amounts, financial data of the subsidiaries, and board opinions on the guarantees. The document is an announcement about financing guarantees and related contractual details, not a full financial report or audit. It does not present comprehensive financial statements or quarterly/yearly results but focuses on capital/financing updates related to guarantees. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3374 characters, which is sufficient for a detailed announcement but not a full annual or interim report.
2023-05-31 Chinese
关于转让全资子公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of 95% equity of a wholly-owned subsidiary by the company. It details the transaction overview, parties involved, financial data of the subsidiary, terms of the agreement, and the impact on the company. It includes audited net asset values and mentions an audit report as a reference but does not contain the audit report itself. The document is relatively short (2636 characters) and focuses on a capital transaction involving equity transfer and investment. This fits the category of Capital/Financing Update (CAP), as it provides updates on company fundraising, financing activities, or capital structure changes. It is not a full annual or interim report, nor an audit report, nor a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2023-05-18 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2022 by 普洛药业股份有限公司. It details the dividend distribution plan approved at the 2022 Annual General Meeting, including dividend amounts, record dates, and payment methods. The text is an announcement of the implementation of the dividend distribution, not the dividend declaration itself or a full financial report. The document length is 2074 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Notice of Dividend Amount (DIV), as it announces the dividend payment details following shareholder approval.
2023-05-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.